N/A N=25 Study of PM Modulation Therapy in Trial Phase
Chronic Pain
Primary: Change in Pain Relative to Baseline and After a Trial Period — 4.2; 2.4 Score on a 11 point scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=106 LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Tumors With CDK4/6 Pathway Activation
Primary: Number of Participants With Solid Tumor Response ≥ 16 Weeks for Based Upon Local Investigator Assessments — 0; 3; 16; 71 Participants
Phase 2 N=80 Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma
Follicular Lymphoma · B-cell Lymphoma · Non-Hodgkin's Lymphoma
Primary: Overall Response Rate (ORR): Proportion of Subjects Achieving the Best Overall Responses of Complete Response (CR) or Partial Response (PR) — 51; 15 Participants
Phase 4 N=50 Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder
Bipolar Disorder
Primary: Change in Serum Brain Derived Neurotrophic Factor (BDNF) — 23.1; 90.7 pg/ml
N/A N=199 The SOLACE-AU Clinical Trial
Severe, Symptomatic Aortic Stenosis
Primary: VARC-2 Composite Safety Endpoint — 12.1 percentage of patients
Phase 2 N=2 Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
Diarrhea · Gastrointestinal Complications · Unspecified Childhood Solid Tumor, Protocol Specific
Primary: Number of Participants With Treatment-free Remission at 1 Year After Study Completion — 2 Participants
Phase 2 N=5 Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease
Mild Cognitive Impairment
Primary: Change in Baseline Standard Uptake Ratio Values (SUVr) of Florbetapir PET at 3 Months — -3.83 standard uptake value ratio
Phase 1 N=42 A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
Healthy
Primary: Pharmacokinetics (PK): Area Under The Drug Concentration Time Curve From Zero to Infinity (AUC-∞) of Rosuvastatin — 80; 78 hours times nanogram per milliliter
Phase 4 N=28 Clinical Trial of Lamotrigine to Reverse Cognitive Impairment in Chronic Corticosteroid-Treated Patients
Memory Impairment Due to Corticosteroid Use · Hypomania Due to Corticosteroid Use · Hippocampal Atrophy Due to Corticosteroid
Primary: Rey Auditory Verbal Learning Test (RAVLT) — 46.1; 40.1 T-scores
Phase 3 N=595 A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Non - Small Cell Lung Cancer NSCLC
Primary: Overall Survival (OS) — 11.7; 6.8; 11.5; 8.7 months — p=0.109
Phase 3 N=115 A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Negative Biopsies at Month 12 — 28; 17 Participants — p=0.0318
Phase 2 N=12 An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
GNE Myopathy
Primary: Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted) — 7461; 9432 hr*ng/mL
Phase 3 N=229 A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic Leukemia · Small-Cell Lymphoma
Primary: Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30 — 78.5; 31.1…
Phase 2 N=31 LEO 124249 Ointment in the Treatment of Alopecia Areata
Alopecia Areata
Primary: Change in Severity of Alopecia Areata Tool (SALT) Score — -3.8; -3.4 units on a scale — p=0.97
N/A N=480 Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
Prostate Cancer Detection
Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio